Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Abstract BACKGROUND Renal impairment (RI) affects 20-40% of newly diagnosed multiple myeloma (NDMM) patients and independently predicts adverse survival. Bortezomib-based triplet regimens (doxorubicin, cyclophosphamide or thalidomide with dexamethasone) have been recommended for multiple myeloma (MM) with RI by International Myeloma Working Group (IMWG). However, these confer only limited survival benefits in such patients, with a reported 2-year overall survival (OS) of ~58%. Novel regimens that simultaneously target myeloma and reverse RI are critically needed. We previously reported at the ASH 2022 Annual Meeting and in Blood Advances (2023;7:7581-84) that PVD triplet therapy (pomalidomide/bortezomib/dexamethasone) in NDMM-RI achieved a 75.4% renal response rate at 3 months (best response 78.7%), without compromising stem cell harvest. Here, we present extended follow-up survival outcomes for this cohort. METHODS In this prospective, open-label, phase 2 trial (ChiCTR2100043748), 61 NDMM-RI patients (eGFR <40 mL/min) were enrolled at 28 Chinese centers (February 2021–January 2022). Key inclusion criteria included cast nephropathy, measurable disease, and no prior anti-myeloma therapy. Patients received up to 9 cycles of PVD induction (pomalidomide 4mg d1-14/21, bortezomib 1.3mg/m² on days 1, 4, 8, and 11 in the first two 21-day cycles and weekly in the following 35-day cycles, dexamethasone 20mg twice per bortezomib dosage) ± autologous stem cell transplantation (ASCT). The primary endpoint was 3-month renal response (IMWG criteria). Secondary endpoints included progression-free survival (PFS) and OS. Survival analyses were performed using the Kaplan-Meier method. RESULTS Of the 61 intention-to-treat patients, 33 (54.1%) completed the planned therapy (13 underwent ASCT, 20 received ≥6 PVD cycles). After a median follow-up of 42 months, 19 patients had disease progression and 17 had died. Causes of deaths were disease progression (n=8), non-MM comorbidities (n=5), and unknown causes (n=4). No new long-term safety signals emerged during the follow-up period. Among the entire PVD cohort (n=61), 57 patients had evaluable PFS data and 60 had evaluable OS data. Median PFS and OS were not reached after 42-month follow-up. The estimated 3-year PFS rate was 74.4% (95% CI: 61.9%-86.9%) and the estimated 3-year OS rate was 80.2% (95% CI: 69.6%-90.8%). Notably, patients achieving renal response had significantly superior OS compared to non-responders (HR 0.327, 95% CI: 0.120-0.893; P=0.029), highlighting renal recovery as a key prognostic factor of survival. CONCLUSION With extended follow-up, this study demonstrates that PVD induction offers survival benefit for NDMM patients with RI in addition to high renal response rates. Achieving renal recovery was strongly associated with improved OS.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-11-03
DOI
https://doi.org/10.1182/blood-2025-5818
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Xiaoxia Chu, Hong‐Hu Zhu, Chunyan Sun, Zhen-Fang Xi et al.
Blood
Multiple Myeloma Research and Treatments
article

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Xiaoxia Chu, Hong‐Hu Zhu, Chunyan Sun, Zhen-Fang Xi, Jingnan Sun, Yuan Jian, Jie Ma, Yaqing Feng, Liping Su, Xuliang Shen, Guohong Su, Yanhong Zhao, Sai-Yin Qimuge, Hebing Zhou, Jing Xiao, Yanping Ma, Da Gao, Shi Minxia, Ying Sun, Yan Yan, Jian Li, Xue Hua, Bao Li, Wen-Ming Chen, Wen Gao, Guorong Jia, Qingming Wang, Wenrong Huang, Yujun Dong, Xiaonan Sun, Guangyu Ma, Hongmei Jing, Weiwei Tian, Long Chang
article en

Abstract

Abstract BACKGROUND Renal impairment (RI) affects 20-40% of newly diagnosed multiple myeloma (NDMM) patients and independently predicts adverse survival. Bortezomib-based triplet regimens (doxorubicin, cyclophosphamide or thalidomide with dexamethasone) have been recommended for multiple myeloma (MM) with RI by International Myeloma Working Group (IMWG). However, these confer only limited survival benefits in such patients, with a reported 2-year overall survival (OS) of ~58%. Novel regimens that simultaneously target myeloma and reverse RI are critically needed. We previously reported at the ASH 2022 Annual Meeting and in Blood Advances (2023;7:7581-84) that PVD triplet therapy (pomalidomide/bortezomib/dexamethasone) in NDMM-RI achieved a 75.4% renal response rate at 3 months (best response 78.7%), without compromising stem cell harvest. Here, we present extended follow-up survival outcomes for this cohort. METHODS In this prospective, open-label, phase 2 trial (ChiCTR2100043748), 61 NDMM-RI patients (eGFR <40 mL/min) were enrolled at 28 Chinese centers (February 2021–January 2022). Key inclusion criteria included cast nephropathy, measurable disease, and no prior anti-myeloma therapy. Patients received up to 9 cycles of PVD induction (pomalidomide 4mg d1-14/21, bortezomib 1.3mg/m² on days 1, 4, 8, and 11 in the first two 21-day cycles and weekly in the following 35-day cycles, dexamethasone 20mg twice per bortezomib dosage) ± autologous stem cell transplantation (ASCT). The primary endpoint was 3-month renal response (IMWG criteria). Secondary endpoints included progression-free survival (PFS) and OS. Survival analyses were performed using the Kaplan-Meier method. RESULTS Of the 61 intention-to-treat patients, 33 (54.1%) completed the planned therapy (13 underwent ASCT, 20 received ≥6 PVD cycles). After a median follow-up of 42 months, 19 patients had disease progression and 17 had died. Causes of deaths were disease progression (n=8), non-MM comorbidities (n=5), and unknown causes (n=4). No new long-term safety signals emerged during the follow-up period. Among the entire PVD cohort (n=61), 57 patients had evaluable PFS data and 60 had evaluable OS data. Median PFS and OS were not reached after 42-month follow-up. The estimated 3-year PFS rate was 74.4% (95% CI: 61.9%-86.9%) and the estimated 3-year OS rate was 80.2% (95% CI: 69.6%-90.8%). Notably, patients achieving renal response had significantly superior OS compared to non-responders (HR 0.327, 95% CI: 0.120-0.893; P=0.029), highlighting renal recovery as a key prognostic factor of survival. CONCLUSION With extended follow-up, this study demonstrates that PVD induction offers survival benefit for NDMM patients with RI in addition to high renal response rates. Achieving renal recovery was strongly associated with improved OS.

BloodVol. 146(Supplement 1)
Qingdao University (CN), Hebei Medical University (CN), Binzhou Medical University (CN), Nanchang University (CN), Shandong University of Aeronautics (CN), Harbin Medical University (CN), Shanxi Medical University (CN), Capital Medical University (CN), Dalian Medical University (CN), Jilin University (CN), Changzhi Medical College (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Kunming Medical University (CN), Peking Union Medical College Hospital (CN), Chinese PLA General Hospital (CN), Beijing Jishuitan Hospital (CN), Yuhuangding Hospital (CN), Cangzhou Central Hospital (CN), People's Liberation Army No. 150 Hospital (CN), Shanxi Provincial Cancer Hospital (CN), Fourth Hospital of Hebei Medical University (CN), Second Affiliated Hospital of Nanchang University (CN), The Third People's Hospital of Dalian City (CN), Beijing Luhe Hospital Affiliated to Capital Medical University (CN), First Affiliated Hospital of Kunming Medical University (CN), Chifeng Municipal Hospital (CN), First Hospital of Jilin University (CN), Wuhan Union Hospital (CN), Peking University First Hospital (CN), Second Hospital of Shanxi Medical University (CN), National Institutes for Food and Drug Control (CN), Affiliated Hospital of Hebei University (CN), First Affiliated Hospital of Dalian Medical University (CN), Peking University Third Hospital (CN), Yantaishan Hospital (CN), First Affiliated Hospital of Harbin Medical University (CN), First Affiliated Hospital of Zhengzhou University (CN), Shanxi Academy of Medical Sciences (CN), Baotou Medical College (CN), Union Hospital (CN), Beijing Chaoyang Emergency Medical Center (CN), Inner Mongolia Medical University (CN)
Openalex Percentile: Top 49%
Multiple Myeloma Research and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.